Therapeutic advances in allergy and rhinology最新文献

{"title":"Temporal and Geographic Variations and Patient Factors in Acute Invasive Fungal Sinusitis: A Scoping Review.","authors":"Keenya Frazier, Abigail Pulsipher, Richard R Orlandi, Kristine A Smith","doi":"10.1177/27534030261450420","DOIUrl":"https://doi.org/10.1177/27534030261450420","url":null,"abstract":"<p><strong>Background: </strong>The relationship between temporal and geographical variations and the incidence of acute invasive fungal sinusitis (AIFS) remains unclear. Furthermore, the impact of social determinants of health on AIFS outcomes is poorly understood. The objective of this scoping review was to summarize the literature on these topics using the Preferred Reporting Items for Systematic and Meta-Analyses Extension for Scoping Reviews guidelines.</p><p><strong>Methods: </strong>A scoping review was conducted using PubMed, Elsevier, and Wiley Online Library during August 2023 for articles that included the following variables related to AIFS: (1) temporal/geographic variations and (2) patient factors.</p><p><strong>Results: </strong>Sixteen studies were identified for inclusion. Associations between AIFS and COVID-19 were observed in certain geographic regions, particularly during the onset of the pandemic when high-dose oral corticosteroids were frequently used. No studies specifically examined the impact of geographic location on the incidence or outcomes in AIFS. Two studies reviewed the relationship between AIFS incidence and season, producing varied results. While both demonstrated seasonal variation in the incidence of AIFS, the findings appeared to be dependent on local climate conditions. Female sex and Black and Hispanic race appeared to be significant prognostic indicators for worse AIFS outcomes. A predominant number of studies included did not report the social determinants of health.</p><p><strong>Conclusion: </strong>This review identifies a lack of comprehensive research on the role of geographic, temporal, and social determinants in AIFS and calls for further studies to bridge these knowledge gaps.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"17 ","pages":"27534030261450420"},"PeriodicalIF":0.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic advances in allergy and rhinology: A new era of scientific excellence and clinical impact.","authors":"Baharudin Abdullah, Aleksandar Peric","doi":"10.1177/27534030261470888","DOIUrl":"https://doi.org/10.1177/27534030261470888","url":null,"abstract":"","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"17 ","pages":"27534030261470888"},"PeriodicalIF":0.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Variants in Allergic Rhinitis Identified by Whole-Exome Sequencing in the Malaysian Population.","authors":"Moath Bseiso, Mohammad Farid Baharin, Muhammad Yusri Musa, Sarina Sulong, Saharuddin Bin Mohamad, Baharudin Abdullah, Adiratna Mat Ripen, Siti Mardhiana Binti Mohamad","doi":"10.1177/27534030261483845","DOIUrl":"10.1177/27534030261483845","url":null,"abstract":"<p><p>Allergic rhinitis (AR) is among the most prevalent allergic diseases in the world and has a large impact on quality of life, school performance, and work productivity. The aim of this exploratory study was to identify the genetic variants that might be associated with AR in the Malaysian population through whole-exome sequencing. A total of 13 AR patients and 10 healthy controls were recruited from the ENT Clinic at the Pusat Kanser Tun Abdullah Ahmad Badawi and Universiti Sains Malaysia Specialist Hospital. Whole-exome sequencing of genomic DNA was performed. To prioritize the variants, bioinformatic analysis was performed according to the American College of Medical Genetics (ACMG) guidelines, and potentially pathogenic variants were looked for. The 5 HLA-DRB1 variants identified (rs1059582, rs17882084, rs17879995, rs11554463, and rs188617679) were classified as potentially pathogenic or likely pathogenic, using ACMG criteria. Of these, rs1059582 had a statistically significant association with AR (<i>P</i> = .0457), which implies that it may be involved in susceptibility to AR. The present preliminary exploratory study revealed that a number of HLA-DRB1 variants, especially HLA-DRB1 rs1059582, are candidate genetic risk factors for AR in the Malaysian population. These results are preliminary and suggest that HLA-DRB1 may be a potential biomarker, but needs to be further validated in larger cohorts.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"17 ","pages":"27534030261483845"},"PeriodicalIF":0.9,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13527364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Endonasal Approach for Surgical Treatment of Nasal and Ethmoidal Malignancies: A Retrospective Multicenter Study.","authors":"Masayoshi Kobayashi, Toyoyuki Hanazawa, Takayuki Nakagawa, Nobuyoshi Otori, Yasushi Fujimoto, Satoru Kodama, Tetsuji Sanuki, Shuho Tanaka, Yosuke Ariizumi, Ken-Ichi Nibu, Mami Matsunaga, Satoru Miyamaru, Naoki Nishio, Takashi Hirano, Takahiro Asakage","doi":"10.1177/27534030261449548","DOIUrl":"10.1177/27534030261449548","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Endoscopic endonasal approach (EEA) has gained widespread acceptance as a surgical approach for treating sinonasal malignancies in the last decade.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;This study examined the validity of the EEA as a standard modality for the surgical treatment of sinonasal malignancies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;A retrospective multicenter cohort study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study included patients with nasoethmoidal malignancies who underwent initial surgical treatment between 2014 and 2016 at 10 tertiary referral hospitals in Japan. The EEA, craniofacial approach (CA), and EEA combined with CA (EEAwCA) were used as the surgical methods.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The total number of participants was 110, with a median posttreatment observation period of 69 months. The olfactory cleft (26%) was the most frequent lesion site. Squamous cell carcinoma (29%) and olfactory neuroblastoma (24%) were the most frequently observed pathological classifications. EEA was performed in early-stage cases, and EEAwCA, which is frequently used for tumors that extend into the orbit and/or intracranial regions, was performed in advanced-stage cases. Negative-margin resection was achieved in 85%, 78%, and 64% of EEA, EEAwCA, and CA cases, respectively; postoperative radiotherapy was performed in 50%, 56%, and 36% of patients with EEA, EEAwCA, and CA, respectively; and the 5-year local control rates were 90%, 78%, and 82% for EEA, EEAwCA, and CA, respectively. &lt;i&gt;En bloc&lt;/i&gt; resection for EEA, and postoperative irradiation for EEA and EEAwCA were associated with fewer local recurrences. Validation of the operation time, hospitalization period, intraoperative blood loss, and postoperative complications demonstrated the low invasiveness of the EEA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The EEA is a minimally invasive surgical modality with preferable oncological outcomes for the treatment of nasoethmoidal malignancies when adequately planned.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Plain language summary: &lt;/strong&gt;&lt;b&gt;A look back at nose cancer surgery using a less invasive method through the nose&lt;/b&gt;.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;This study looked at a newer, less invasive surgery called the endoscopic endonasal approach (EEA), which goes through the nose to remove tumors in the nose and nearby areas. The goal was to see if this method could be used as a standard treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;How the study was done: &lt;/strong&gt;Researchers looked back at 110 patients in Japan who had surgery for cancer in the nose and surrounding areas between 2014 and 2016. They had surgery using one of three methods:EEA (through the nose)CA (a more traditional open surgery)EEA combined with CA (used for more serious cases).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;What they found: &lt;/strong&gt;1)Most patients had tumors in a part of the nose related to the sense of smell.2)The most common types of cancer were squamous cell carcinoma and a rare nerve-related tumor.3)The EEA wa","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"17 ","pages":"27534030261449548"},"PeriodicalIF":0.9,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148347615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness of Dupilumab in Treating Pediatric Refractory Allergic Fungal Rhinosinusitis.","authors":"Hussain J Aljubran, Maria R Alabdulaal, Ali A Alnasser, Ali R Alhayek, Mohammad S Alahmari, Ali Almomen","doi":"10.1177/27534030261454553","DOIUrl":"10.1177/27534030261454553","url":null,"abstract":"<p><p>Allergic fungal rhinosinusitis (AFRS) is defined as a benign, extramucosal, non-invasive fungal condition of the paranasal sinuses, resulting from a type 1 IgE-mediated hypersensitivity reaction. AFRS is most commonly seen in young adults, although it also occurs in the pediatric population. Currently, biological therapy has been proposed as an effective treatment for adult patients with AFRS. However, the use of biologics in the pediatric population has not yet been introduced in the literature. Hence, this study reports a unique case involving the use of Dupilumab to treat a pediatric patient with refractory AFRS and bronchial asthma. A 13-year-old girl with a long-standing history of bronchial asthma who was diagnosed with AFRS, started Dupilumab with a loading dose of 600 mg, followed by 300 mg biweekly. The patient showed improvement in her condition after the initiation of Dupilumab, in terms of clinical, endoscopic, and radiological outcomes. Additionally, Dupilumab was shown to be a helpful treatment in controlling the patient's bronchial asthma. In conclusion, Dupilumab appears to be a promising treatment for pediatric patients with refractory AFRS to improve their clinical, endoscopic, and radiological outcomes. However, further studies are needed in the future to validate these findings.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"17 ","pages":"27534030261454553"},"PeriodicalIF":0.9,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Dupilumab Treatment in Patients With Type 2 Inflammation: A Real-Life Integrated Experience.","authors":"Sara Torretta, Gioia Piatti, Chiara Catalano, Silvia Ferrucci, Mirta Cavallini, Federica Rivolta, Chiara Bellocchi, Alice D'Adda, Ludovica Battilocchi, Simona Tavecchio, Lorenzo Pignataro","doi":"10.1177/27534030241312540","DOIUrl":"10.1177/27534030241312540","url":null,"abstract":"<p><strong>Background: </strong>Type 2 inflammation plays a pivotal role in various allergic and inflammatory diseases, including chronic rhinosinusitis, asthma, atopic dermatitis, and eosinophilic esophagitis. Dupilumab is one of the emerging therapeutic targets that modulate the key mediators and cellular players involved in type 2 inflammation, aiming to improve the immune response and the quality of life of the patient.</p><p><strong>Objective: </strong>Here, we describe the experience made on 792 patients enrolled by several specialists of a multidisciplinary team working on inflammatory type 2 diseases.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Methods: </strong>Patients were treated with dupilumab according to the prescribed indications and were evaluated by several exams, tests, and questionnaires at baseline (T0) and after 12 (T1), 18 (T2), and 24 (T3) months.</p><p><strong>Results: </strong>Overall, dupilumab exerts beneficial effects as demonstrated both by patients-reported outcomes and by objective assessments. Compared to baseline, all examined efficacy indicators showed an improvement after 12 months, with positive effects sustained through the 2 years of observation. Our results align with several previous trials.</p><p><strong>Conclusion: </strong>Understanding the interconnection between different type 2 inflammatory diseases provides insight into potential avenues for precision medicine approaches and targeted therapies.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"16 ","pages":"27534030241312540"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis and Risk Factors of Recurrence in a Tertiary Care Teaching Hospital.","authors":"Ahmad Aldajani, Ahmad Alroqi, Ali Alrashidi, Anas Alsaif, Saif Almeshari, Mohammed Aldwaighri, Saud Alromaih, Mohammad O Aloulah, Abdulaziz S Alrasheed, Surayie Aldousary, Saad Alsaleh","doi":"10.1177/27534030241274764","DOIUrl":"10.1177/27534030241274764","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic sinus surgery (ESS) has become the gold standard for treating patients with chronic rhinosinusitis (CRS) refractory to medical therapy. It is considered a relatively safe and effective procedure in all age groups, with overall success rates ranging from 76% to 97.5%. However, failure of primary endoscopic sinus surgery (PESS) occurs at a rate ranging from 2% to 24%. Patients who are still symptomatic after PESS and optimal medical therapy are candidates for revision endoscopic sinus surgery (RESS).</p><p><strong>Objectives: </strong>to study the outcomes of ESS and assess the risk factors of recurrence of nasal polyps, as well as to compare the outcomes of PESS and RESS at a tertiary care teaching hospital.</p><p><strong>Design: </strong>A retrospective cross-sectional study.</p><p><strong>Methods: </strong>This study is conducted on patients with CRS with nasal polyps (CRSwNP) who underwent ESS at King Saud University Medical City (KSUMC) between May 2015 and December 2021. During this period, ESS was performed 470 times for CRSwNP. The Sinonasal Outcome Test 22 (SNOT-22) questionnaire, the Lund-Kennedy (LK) score, the Lund-MacKay (LM) score, and the polyp grading system were used to evaluate subjective and objective outcomes. They were scored preoperatively and from 6 to 12 months postoperatively.</p><p><strong>Results: </strong>Out of the 470 endoscopic sinus surgeries, 321 (68.3%) were PESS and 149 (31.7%) were RESS. Asthma, aspirin sensitivity, and Samter's triad were observed more in the RESS group. The LK and LM scores were significantly different between primary and revision sinus surgeries, revealing that PESS patients had better postoperative LK and LM scores. The RESS patients had significantly worse postoperative SNOT-22 scores compared to PESS patients.</p><p><strong>Conclusion: </strong>Lund-MacKay, Lund-Kennedy, and SNOT-22 scores improved after ESS for both primary and revision ESS patients, with better outcomes observed after PESS compared to RESS. The presence of asthma, aspirin sensitivity, Samter's Triad, high-grade nasal polyps, and older age were identified as risk factors for CRSwNP recurrence, which may require RESS.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"15 ","pages":"27534030241274764"},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Vision Loss in Patients With Allergic Fungal Rhinosinusitis: A Case Series.","authors":"Hussain Allami, Hadeel Muhammad Alarfaj, Hisham Almousa, Razan Abdullah Aldhahri, Rayan Alfallaj, Abdulmajeed Alharbi, Sarah S Alotaibi, Ghassan Alokby, Saad Alsaleh","doi":"10.1177/27534030231214400","DOIUrl":"https://doi.org/10.1177/27534030231214400","url":null,"abstract":"<p><p>Allergic fungal rhinosinusitis (AFRS) is a subtype of chronic noninvasive sinusitis accounting for 7.8% (0.2%-26.7%) of all chronic rhinosinusitis cases. A definitive diagnosis is usually made after sinus surgery. Successful treatment requires a combination of surgical and medical management. Although orbital involvement is relatively common, reports on optic neuropathy and acute vision loss are limited. Herein, we present a series of 3 patients with AFRS who presented with acute visual loss as the chief complaint. All 3 patients were otherwise healthy adults in their early 20s with extensive nasal polyps on endoscopic nasal examination and bone erosion in the bilateral orbits and lateral wall of the sphenoid sinus on the affected side on imaging. One of the 3 patients had bilateral cranial nerve IV defects in addition to cranial nerve III defects. All patients underwent endoscopic sinus surgery with orbital decompression and were followed up postoperatively by both otolaryngology and ophthalmology services with endoscopic and radiologic evaluation. Unfortunately, no meaningful improvement in vision was observed in any patient despite successful nerve decompression. Prompt diagnosis and early medical and surgical intervention are warranted to prevent complications in patients with AFRS with orbital extension.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"14 ","pages":"27534030231214400"},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10704942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central Compartment Atopic Disease and Its Surgical Outcomes: Olfactory Changes and Technical Notes.","authors":"Sheng-Kai Huang, Ching-Hung Hsieh, Ming-Chian Weng, Jen-Tsung Lai, Ping-Hung Shen","doi":"10.1177/27534030231217423","DOIUrl":"10.1177/27534030231217423","url":null,"abstract":"<p><strong>Background: </strong>Central compartment atopic disease (CCAD) is a recent, novel phenotype of chronic rhinosinusitis. Only a few studies have assessed olfactory function in patients with CCAD.</p><p><strong>Objectives: </strong>We aimed to investigate olfactory function changes after functional endoscopic sinus surgery (FESS) in patients with CCAD and proposed some surgical techniques to enhance the postoperative olfactory outcomes in such patients.</p><p><strong>Design: </strong>A retrospective cohort study.</p><p><strong>Methods: </strong>We collected data from 23 patients (8 men and 15 women) with CCAD who underwent FESS performed by a surgeon in Taiwan, between June 2018 and December 2021. The demographic data, olfactory function, and serum and tissue eosinophil percentages of the included patients were analyzed. The Top International Biotech Smell Identification Test (TIBSIT; Top International Biotech, Taipei, Taiwan) was used to assess olfactory function.</p><p><strong>Results: </strong>Of the 23 patients, most (95%) showed a positive reaction to aeroallergens, and 2 patients (8.7%) had asthma. Ten patients (43.5%) had peripheral eosinophilia, and 9 (39%) had eosinophilic nasal polyps. Moreover, the patients presented with variable olfactory dysfunction; the mean preoperative TIBSIT (pr-TIBSIT) score was 12.8 ± 2.3 (range: 0-43), whereas the mean postoperative TIBSIT (po-TIBSIT) score was 29.2 ± 1.9 (range: 16-44). The po-TIBSIT score was significantly better than the pre-TIBSIT score (paired <i>t</i> test, <i>P</i> < .0001). The improvement in olfactory function was not significantly correlated with the patients' age, serum eosinophil percentages, and nasal polyp eosinophil counts.</p><p><strong>Conclusion: </strong>Our findings indicate that CCAD is significantly associated with olfactory dysfunction and that FESS can effectively improve olfactory function. To optimize postoperative olfactory outcomes, precise removal of polyps from the olfactory cleft without damaging the neuroepithelium is recommended. Our study provides valuable insights into the management of CCAD patients undergoing FESS and can guide surgical decision-making to achieve optimal olfactory function outcomes.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"14 ","pages":"27534030231217423"},"PeriodicalIF":0.0,"publicationDate":"2023-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Incidence and Disease Course Among Patients at an Allergy Department.","authors":"Louise E van der Aa, Inge S van Egmond, Martijn van der Sluijs, A A Sophie den Otter, Nadie H M Bosmans, Sabine E van Beek, Angela Hartman, Niels A D Guchelaar, Paul L A van Daele, Maurits S van Maaren, P Martin van Hagen, Maud A W Hermans, Saskia M Rombach","doi":"10.1177/27534030231172391","DOIUrl":"10.1177/27534030231172391","url":null,"abstract":"<p><strong>Background: </strong>Since the coronavirus pandemic in 2020, there is not much reported about the disease course of COVID-19 in patients with allergic diseases.</p><p><strong>Objectives: </strong>The aim of this study was to investigate the cumulative incidence and severity of COVID-19 among patients from the allergy department compared with the general Dutch population and people from their household.</p><p><strong>Design: </strong>We conducted a comparative longitudinal cohort study.</p><p><strong>Methods: </strong>In this study patients of the allergy department were included with their household members as a control group. Data from the beginning of the pandemic were systematically obtained through questionnaires by telephonic interviews and retrieved from electronic patient files between October 15, 2020 and January 29, 2021. Main outcomes were confirmed SARS-CoV-2 infection, disease duration, hospitalization, intensive care admission, and mortality. Questions regarding applied social distancing measures were inventoried as well.</p><p><strong>Results: </strong>Three hundred and eighty nine patients (median age 39.1 (18.7-84.7) years, 69.9% female) and 441 household members (median age 42.0 (18.0-91.5), 44.1% female) were included. The cumulative COVID-19 incidence in patients was higher compared with the general population (10.5% vs 5.6%, <i>P</i> < .001). In total, 41 (10.5%) patients attending the allergy clinic compared to 38 (8.6%) household members were infected with SARS-CoV-2 (<i>P</i> = .407). Median disease duration was 11.0 (0.0-61.0) days in patients compared to 10.5(1.0-232.0) days in household members (<i>P</i> = .996).</p><p><strong>Conclusion: </strong>The cumulative COVID-19 incidence in patients from the allergy cohort was higher compared with the general Dutch population, but similar compared with household members. There was no difference in symptoms, disease duration, or hospitalization rate between the allergy cohort and their household members.</p>","PeriodicalId":75217,"journal":{"name":"Therapeutic advances in allergy and rhinology","volume":"14 ","pages":"27534030231172391"},"PeriodicalIF":0.9,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9868981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}